sec filing
NA
NASDAQ · NAMS
NewAmsterdam Pharma Company N.V.
Healthcare · Biotechnology
$21.93
Up+$0.75 (+3.54%)
Updated Sep 18, 2026, 8:13 AM
SID Score
3.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.1B
- P/E ratio
- -19.49
- Dividend yield
- 0.00%
- 52-week range
- $21.02 – $42.21
- Volume
- 2.31M
- Avg. volume
- 1.15M
Price performance
NAMS price history
1M range · 20 trading sessions · Daily adjusted prices
NAMS closed at $21.93 after 20 trading sessions, down 21.06% for the selected period.
- Last close
- $21.93
- Period change
- -21.06%
- Period low
- $21.16
- Period high
- $27.87
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $21.59 | $23.1125 | $21.455 | $21.93 | 2.31M |
| Sep 16, 2026 | $22.07 | $22.15 | $21.02 | $21.18 | 1.24M |
| Sep 15, 2026 | $22.32 | $22.6247 | $21.08 | $21.16 | 1.73M |
| Sep 14, 2026 | $22.96 | $22.96 | $22.34 | $22.36 | 1.08M |
| Sep 11, 2026 | $22.11 | $23.00 | $21.23 | $22.80 | 1.6M |
| Sep 10, 2026 | $22.44 | $22.95 | $21.80 | $21.86 | 2.73M |
| Sep 9, 2026 | $25.345 | $25.525 | $22.34 | $22.79 | 2.32M |
| Sep 8, 2026 | $24.02 | $26.19 | $23.24 | $25.63 | 3.8M |
| Sep 4, 2026 | $25.65 | $25.7499 | $25.10 | $25.40 | 709.5K |
| Sep 3, 2026 | $25.68 | $25.99 | $25.24 | $25.85 | 581.38K |
| Sep 2, 2026 | $25.15 | $26.0053 | $25.00 | $25.59 | 979.91K |
| Sep 1, 2026 | $25.27 | $25.43 | $24.80 | $24.92 | 714.36K |
| Aug 31, 2026 | $25.65 | $25.65 | $24.80 | $25.34 | 1.55M |
| Aug 28, 2026 | $26.66 | $26.875 | $25.53 | $25.90 | 1.04M |
| Aug 27, 2026 | $27.15 | $27.60 | $26.67 | $26.79 | 626.83K |
| Aug 26, 2026 | $27.22 | $27.61 | $26.71 | $27.40 | 758.73K |
| Aug 25, 2026 | $27.00 | $28.01 | $27.00 | $27.34 | 1.99M |
| Aug 24, 2026 | $27.80 | $27.97 | $26.6701 | $26.85 | 1.15M |
| Aug 21, 2026 | $27.99 | $28.35 | $27.66 | $27.87 | 525.43K |
| Aug 20, 2026 | $28.26 | $28.43 | $27.53 | $27.78 | 744.36K |
Latest NAMS news
The latest Smart Investors Daily articles mentioning NAMS.
Stock researchResearch & News · Competitors
Loading stock research…